Aankondiging • Feb 24

+ 1 more update

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery. The FDA evaluated Dupixent under Priority Review for the treatment of AFRS, which is reserved for medicines that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions. This approval expands our approved indications in sino-nasal diseases to now include AFRS, alongside chronic rhinosinusitis with nasal polyps. “Allergic fungal rhinosinusitis (AFRS) is a disease that can leave both children and adults with inflamed nasal passages, nasal polyps and thick mucus causing constant nasal congestion. Some patients can also experience more serious complications like deterioration of bone around the sinuses and facial deformities,” said Kenneth Mendez, President and CEO, Asthma and Allergy Foundation of America (AAFA). “As the first treatment specifically approved for AFRS, Dupixent offers the potential for relief to adults and children six years and older struggling with potentially debilitating symptoms.” AFRS is a chronic type 2 inflammatory disease. It is a specific subtype of chronic rhinosinusitis distinctly caused by an intense allergic hypersensitivity to fungi. It primarily affects people living in warm, humid climates where fungal spores are common in the environment. It can lead to nasal polyps, nasal congestion, loss of smell, thick mucus discharge, poor health-related quality of life, and patients can also experience bone loss around the sinus cavities and facial deformities. AFRS can be a severe and hard-to-treat form of chronic rhinosinusitis because it may not respond well to available options. Current standard-of-care treatment is surgery and prolonged courses of systemic steroids; however, disease recurrence is not uncommon. “With this approval, Dupixent once again demonstrates its value in advancing the treatment landscape for a chronic type 2 inflammatory disease with high unmet need,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “Beyond reducing nasal signs and symptoms, Dupixent reduced the need for surgery or systemic corticosteroids with fewer patients having bone erosion in the sinuses. These results underscore its potential to establish a new standard of care for people living with AFRS. This ninth FDA approval for Dupixent, the most widely used innovative branded antibody medicine, strengthens the established efficacy and body of evidence that IL-4 and IL-13 are major drivers of type 2 inflammation across many chronic diseases.” The FDA approval is supported by the LIBERTY-AFRS-AIMS Phase 3 trial, in which 62 adults and children aged 6 years and older with AFRS were randomized to receive an age- and weight-based dose of Dupixent (200 mg or 300 mg) every two or four weeks (n=33) or placebo (n=29). The differences for Dupixent compared to placebo were as follows: Primary Endpoint: Sinus opacification scores (a measure of extent of sinus involvement by the disease as assessed by computed tomography [CT] scans) improved by 50% versus 10% at Week 52 (7.36-point placebo-corrected reduction; p<0.0001); a significant reduction in sinus opacification scores was also observed at Week 24 (p<0.0001). Secondary Endpoints: Select nasal signs and symptoms Patient-reported nasal congestion/obstruction improved by 67% versus 25% at Week 24 (0.87-point placebo-corrected reduction; p<0.0001), with continued improvement at Week 52 to 81% compared to 11% (1.40-point placebo-corrected reduction; p<0.0001). Nasal polyp size (as assessed by endoscopy) reduced by 61% versus 15% at Week 24 (2.36-point placebo-corrected reduction; p<0.0001), with continued reduction of 63% compared to 4% up to Week 52 (2.77-point placebo-corrected reduction; p<0.0001). Sense of smell Patient-reported loss of smell reduced by 67% versus 19% at Week 24 (0.89-point placebo-corrected reduction; p<0.0001). Treatment burden 92% reduction in the risk of systemic corticosteroid use and/or need of surgery (29% fewer proportion of patients; p=0.0010) over 52 weeks. 3% or 0% of patients on Dupixent received systemic corticosteroids or had surgery, respectively, compared to 31% or 7% of patients on placebo. The safety results in the LIBERTY-AFRS-AIMS trial were similar to the known safety profile of Dupixent in CRSwNP. In pooled data from two pivotal CRSwNP trials in adults, the most common adverse reactions (=1%) in the U.S. Prescribing Information more frequently observed in patients on Dupixent compared to placebo were injection site reactions, conjunctivitis, arthralgia, gastritis, insomnia, eosinophilia, and toothache. “Before Dupixent, people living with allergic fungal rhinosinusitis had to rely on treatments that left them potentially vulnerable to regrowth of nasal polyps and thick mucus that could rob them of their sense of smell,” said Alyssa Johnsen, M.D., Ph.D., Global Therapeutic Area Head, Immunology Development at Sanofi. “As the first medicine approved specifically for AFRS, Dupixent has been proven to lessen multiple signs and symptoms of disease, help break the cycle of recurrence, and reduce the risk for subsequent surgeries and corticosteroids by 92%. We look forward to working with regulators in other countries to bring this innovative option to more patients in need.” Additional submissions are planned to other regulatory authorities around the world. About LIBERTY-AFRS-AIMS The LIBERTY-AFRS-AIMS Phase 3 trial was a randomized, double-blind, placebo-controlled trial assessing the safety and efficacy of Dupixent in adults and children aged 6 years and older with AFRS. The 52-week trial included an age- and weight-based dose of Dupixent (300 mg every two weeks for adults and children weighing =60 kg, 200 mg every two weeks for children weighing =30 kg to <60 kg or 300 mg every four weeks for children weighing =15 kg to <30 kg) or placebo. More than 80% of patients had a history of type 2 comorbidities. The primary endpoint assessed change from baseline in sinus opacification assessed by CT scans using the Lund-Mackay score (LMK; scale: 0-24) at Week 52. Secondary endpoints assessed at Week 24 included: Change from baseline in patient-reported nasal congestion (NC; scale: 0-3). Change from baseline in nasal polyp score (NPS; scale: 0-8) as measured by endoscopy. LMK score. Change from baseline in patient-reported loss of smell (LoS; scale: 0-3). Some secondary endpoints were also assessed at Week 52 in addition to proportion of patients requiring surgery or systemic corticosteroids during the treatment period.

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	4.9yrs

Naam	Positie	Tenure	Compensatie	Eigendom
Belen Garijo Lopez	CEO & Director	less than a year	geen gegevens	geen gegevens
François-Xavier Roger	Executive VP & CFO	2.4yrs	geen gegevens	geen gegevens
Michael Quigley	Chief Scientific Officer & Head of Research	no data	geen gegevens	geen gegevens
Thomas Larsen	Head of Investor Relations & General Medicines	2.7yrs	geen gegevens	geen gegevens
Jamie Haney	Executive VP & General Counsel	no data	geen gegevens	geen gegevens
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	22.1yrs	geen gegevens	geen gegevens
Veronique Jaillet	Executive VP & Interim Chief People Officer	less than a year	geen gegevens	geen gegevens
Fabrizio Gaudi	Head of Austrian	7.7yrs	geen gegevens	geen gegevens
Erik Wallström	Head of Therapeutic Area - Neurology Development	no data	geen gegevens	geen gegevens
Thomas Triomphe	Executive Vice President of Vaccines	8.7yrs	geen gegevens	geen gegevens
Karin Knobe	TA Head of Rare Diseases & Rare Blood Disorders Development	no data	geen gegevens	geen gegevens
Pablo Sardi	TA Head of Rare & Neurologic Diseases Research	no data	geen gegevens	geen gegevens

Naam	Positie	Tenure	Compensatie	Eigendom
Belen Garijo Lopez	CEO & Director	less than a year	geen gegevens	geen gegevens
Jean-François Dehecq	Honorary Chairman	16.3yrs	€4.71m	geen gegevens
Serge Weinberg	Honorary Chairman	3.3yrs	€324.96k	geen gegevens
Lise Kingo	Independent Director	6.4yrs	€162.00k	0.000080% € 71.2k
Frederic Oudea	Independent Chairman	3.3yrs	€884.84k	0.000080% € 71.2k
Rachel Duan	Independent Director	6.4yrs	€151.00k	0.000080% € 71.2k
Carole Ferrand	Independent Director	4.3yrs	€208.75k	0.000080% € 71.2k
Barbara Lavernos	Director	5.4yrs	€162.00k	0.000080% € 71.2k
Clotilde Delbos	Independent Director	2.4yrs	€197.75k	0.000080% € 71.2k
Emile Voest	Independent Director	4.3yrs	€186.75k	0.000080% € 71.2k
Christophe Babule	Director	7.6yrs	€156.50k	0.000080% € 71.2k
Wolfgang Laux	Employee Representative Director	5.4yrs	€129.00k	geen gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/09/09 07:42
Aandelenkoers aan het einde van de dag	2026/09/09 00:00
Inkomsten	2026/06/30
Jaarlijkse inkomsten	2025/12/31

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

Analist	Instelling
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
null null	Banco de Sabadell. S.A.

Sanofi Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Sanofi Announces Management Changes

Sanofi Announces Board and Committee Changes

Sanofi, Annual General Meeting, Apr 29, 2026

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Recent updates

New major risk - Dividend sustainability

Sanofi Shuts Down RSV Vaccine Clinical Trial For Infants And Toddlers After Infant Death

Sanofi Receives European Commission Approval For MenQuadfi Extension To Infants From Six Weeks Of Age Against Invasive Meningococcal Disease

Second quarter 2026 earnings released: EPS: €0.29 (vs €1.01 in 2Q 2025)

New minor risk - Profit margin trend

Sanofi Reports Impairment of Intangible Assets for the Second Quarter Ended June 30, 2026

Sanofi to Report Q1, 2027 Results on Apr 23, 2027

Sanofi to Report Q2, 2027 Results on Jul 29, 2027

Sanofi Discontinues Clinical Development of Amlitelimab in Atopic Dermatitis

Sanofi Announces Management Changes

Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector

Sanofi Nexviazyme Meets All Primary and Secondary Endpoints in Infantile-Onset Pompe Disease Phase 3 Study

Sanofi Receives European Commission Approval For Cenrifki (Tolebrutinib) As The First Disability-Targeting Medicine For Secondary Progressive Multiple Sclerosis Without Relapses

Sanofi Receives Approval for Sarclisa Subcutaneous Formulation in Japan for Multiple Myeloma

Sanofi Receives Accelerated Approval for Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes

Sanofi Provides Update On Mobilize Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy

Sanofi Receives European Commission Approval For Sarclisa Subcutaneous As First Anticancer Treatment Administered Via On-Body Injector

The US Food and Drug Administration Accepts Sanofi’s venglustat for priority review in the US to treat type 3 Gaucher disease

Sanofi Demonstrates Superiority Of Efdoralprin Alfa Over Standard-Of-Care Augmentation Therapy In Achieving Higher Functional Alpha-1 Antitrypsin Levels In Alpha-1 Antitrypsin Deficiency

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi Announces Board and Committee Changes

First quarter 2026 earnings released: EPS: €1.32 (vs €1.38 in 1Q 2025)

Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Sanofi Receives US Approval for Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children

Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike in Head-To-Head Study

Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria

Sanofi Becomes Market Authorization Holder for Nuvaxovid in Canada

Sanofi Announces Lunsekimig Meets Primary And Key Secondary Endpoints In Phase 2 Respiratory Studies In Asthma And CRSwNP

Sanofi Announces EU Approval of Rezurock for Treatment of Chronic Graft-Versus-Host Disease

Sanofi Presents New Results from Amlitelimab Phase 3 Studies in Atopic Dermatitis

Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid

Sanofi Earns Breakthrough Therapy Designation in the Us for Venglustat for Type 3 Gaucher Disease

Sanofi, Annual General Meeting, Apr 29, 2026

Dividend increased to €4.12

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Sanofi's Rilzabrutinib Designates Breakthrough Therapy in the Us and Orphan Drug in Japan for the Treatment of Cold Autoimmune Hemolytic Anemia

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi (ENXTPA:SAN) completed the acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX).

Sanofi's Venglustat Met All Primary Endpoints in A Phase 3 Study of Type 3 Gaucher Disease

Sanofi’s Rezurock Recommends for EU Approval by the CHMP to Treat Chronic Graft-vs-Host Disease

New minor risk - Dividend sustainability

Full year 2025 earnings released: EPS: €4.05 (vs €4.39 in FY 2024)

Sanofi Provides Earnings Guidance for the Year 2026

Sanofi Proposes Dividend for 2025

Sanofi's Amlitelimab Confirms its Potential in Atopic Dermatitis

Sanofi Announces Approval of Myqorzo and Redemplo in China

Sanofi's Tzield Accepts for Priority Review in the Us for Young Children with Stage 2 Type 1 Diabetes

Sanofi (ENXTPA:SAN) agreed to acquire Dynavax Technologies Corporation (NasdaqGS:DVAX) for $1.9 billion.

Sanofi Provides Update on Tolebrutinib in Primary Progressive Multiple Sclerosis

Sanofi's Qfitlia and Cablivi Approves in China, Expanding Care for Rare Diseases

Sanofi (ENXTPA:SAN) completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Sanofi's Teizeild Recommends for EU Approval by the CHMP for Patients with Stage 2 Type 1 Diabetes

Sanofi Announces Positive Results from the pivotal LIBERTY- AFRS-AIMS Phase 3 Study

Third quarter 2025 earnings released: EPS: €2.32 (vs €2.25 in 3Q 2024)

Sanofi Announces New Data from the Alphamedix-02 Phase 2 Study Evaluating Alphamedix

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Sanofi's Tzield Accepts for Expanded Review in the US for Stage 3 Type 1 Diabetes Through FDA Commission's National Priority Voucher Pilot Program

Sanofi's High-Dose Influenza Vaccine Demonstrates Superior Protection for Older Adults Against Hospitalization vs Standard-Dose

Sanofi Provides Update on Regulatory Review in the EU for Rezurock to Treat Chronic Graft-Vs-Host Disease

Sanofi's Wayrilz Recommends for Eu Approval by the CHMP to Treat Immune Thrombocytopenia

Sanofi Announces Positive Results from the ALPHAMEDIX-02 Phase 2 Study

Sanofi to Report Q3, 2026 Results on Oct 30, 2026

Sanofi Expands Patient Affordable Program by Offering Access to All Its Insulins for $35 Per Month in the US

Sanofi Announces its SAR446268 Receives US Fast Track Designation for Treatment of Non-Congenital Myotonic Dystrophy Type 1